Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

 Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

Shots:

  • Sosei Heptares to receive $26M as up front and near-term payment, up to $1B as research, development and commercialization milestones and royalties on sales. Genentech to get exclusive WW rights to develop & commercialize therapies for each novel target
  •  The focus of the agreement is to combine Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Genentech’s discovery, development and therapeutic area expertise directed for developing multiple GPCR targets nominated by Genentech
  • Sosei Heptares’ StaR technology forms the backbone of integrated SBDD platform unlocking GPCRs through an advanced understanding of their structure and delivers therapies across multiple therapeutic areas including CNS, immuno-oncology, gastroenterology & inflammation

Click here to read full press release/article | Ref: PRNewswire | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post